We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$10.2B
1-Year Est. Return
149.19%
This Fund
S&P 500
This Quarter
Est. Return
+43.47%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$10.2B
AUM Growth
+$2.44B
(+32%)
Cap. Flow
+$517M
Cap. Flow
% of AUM
5.08%
Top 10 Holdings %
Top 10 Hldgs %
73.3%
Holding
41
New
11
Increased
10
Reduced
6
Closed
8
Top Buys
| 1 |
United Therapeutics
UTHR
|
+$272M |
| 2 |
Celcuity
CELC
|
+$256M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$241M |
| 4 |
Revolution Medicines
RVMD
|
+$142M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$101M |
Top Sells
| 1 |
MRUS
Merus
MRUS
|
+$334M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$188M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$141M |
| 4 |
TRML
Tourmaline Bio
TRML
|
+$122M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$118M |
Sector Composition
| 1 | Healthcare | 97.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$22.3B
| $1.27B | 12.48% |
2,606,060
+583,838
| +29% | +$272M |
|
2
Ascendis Pharma A/S
ASND
$17.5B
| $1.09B | 10.71% |
5,111,111
+1,111
| +0% | +$229K |
|
3
Madrigal Pharmaceuticals
MDGL
$12.3B
| $1.05B | 10.35% |
1,807,500
-25,500
| -1% | -$13M |
|
4
argenx
ARGX
$54.4B
| $833M | 8.18% |
990,000
| – | – |
|
5
Krystal Biotech
KRYS
$10.1B
| $712M | 7% |
2,888,888
+111,111
| +4% | +$23.4M |
|
6
Arrowhead Research
ARWR
$10.3B
| $705M | 6.93% |
10,625,000
-275,000
| -3% | -$13.5M |
|
7
Kymera Therapeutics
KYMR
$9.29B
| $582M | 5.72% |
7,474,747
+1,124,747
| +18% | +$76M |
|
8
Structure Therapeutics
GPCR
$3.65B
| $456M | 4.48% |
6,555,555
+1,400,000
| +27% | +$57.2M |
|
|
RNAM
9
DELISTED
Avidity Biosciences
RNAM
| $393M | 3.87% |
5,455,000
-2,190,000
| -29% | -$141M |
|
|
CNTA
10
DELISTED
Centessa Pharmaceuticals
CNTA
| $364M | 3.58% |
14,555,555
+3,747,475
| +35% | +$94.9M |
|
|
11
Celcuity
CELC
$5B
| $310M | 3.05% |
+3,111,111
| New | +$256M |
|
|
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
| $307M | 3.02% |
12,222,222
| – | – |
|
13
Vera Therapeutics
VERA
$3.08B
| $298M | 2.93% |
5,888,888
-321,112
| -5% | -$11.4M |
|
|
14
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| $256M | 2.52% |
+2,100,000
| New | +$241M |
|
15
Xenon Pharmaceuticals
XENE
$6.53B
| $243M | 2.39% |
5,424,444
+24,444
| +0.5% | +$1.03M |
|
|
TERN
16
DELISTED
Terns Pharmaceuticals
TERN
| $176M | 1.73% |
+4,350,000
| New | +$101M |
|
|
17
Revolution Medicines
RVMD
$39.3B
| $173M | 1.7% |
+2,170,000
| New | +$142M |
|
18
uniQure
QURE
$2.89B
| $147M | 1.45% |
6,150,000
+1,705,556
| +38% | +$65.8M |
|
|
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
| $134M | 1.32% |
2,900,000
+322,223
| +13% | +$17.7M |
|
20
Ocular Therapeutix
OCUL
$2.12B
| $131M | 1.29% |
10,777,777
+527,777
| +5% | +$6.41M |
|
21
Taysha Gene Therapies
TSHA
$1.67B
| $119M | 1.17% |
21,700,000
| – | – |
|
|
DFTX
22
Definium Therapeutics
DFTX
$6.1B
| $67M | 0.66% |
+5,000,000
| New | +$61.9M |
|
23
PTC Therapeutics
PTCT
$6.5B
| $52M | 0.51% |
+685,000
| New | +$49.8M |
|
24
Viridian Therapeutics
VRDN
$2.1B
| $46.7M | 0.46% |
+1,500,000
| New | +$41.1M |
|
|
ORKA
25
Oruka Therapeutics
ORKA
$5.21B
| $40.4M | 0.4% |
1,333,340
| – | – |
|
Similar funds
GI
IIM
RA
GT
VPIM
OIA
ECM
BEI